Investment
Features
FeesSafety
Academy
More
Pluang+

JPMorgan Core Plus Bond ETF upgraded to Buy for strong risk management and potential 7%+ returns.

Analyst Insights
22 Apr 2026
Seeking Alpha
View Source
Bullish
pluang ai news

The JPMorgan Core Plus Bond ETF (JCPB) has been upgraded to a Buy rating due to significant improvements in downside risk management and portfolio construction. The fund now features a 6.1-year duration, a 4.7% SEC yield, and a 5.22% portfolio yield to maturity, with 88% investment-grade exposure and $11 billion in assets under management. Active management allows JCPB to adapt to macroeconomic volatility, outperforming peers in recent risk/reward metrics and aligning well with current interest rate dynamics. With interest rates currently overextended and inflation expectations high, JCPB is positioned to potentially deliver total returns exceeding 7% if the Federal Reserve cuts rates.

More News

Health plan cuts machine-readable file production from 45 days to under 24 hours with TALON integration

Health plan cuts machine-readable file production from 45 days to under 24 hours with TALON integration

A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...

Others
Neutral
55 minutes ago
ASUS launches new durable Chromebooks CM15 and CM32 with long battery life and Google AI features in the US

ASUS launches new durable Chromebooks CM15 and CM32 with long battery life and Google AI features in the US

ASUS has introduced two new Chromebooks in the US market: the budget-friendly CM15 laptop and the versatile CM32 Detachable 2-in-1 device. Both run on the MediaTek Kompanio 540 processor, offer up to 12 hours of battery life, and feature military-gra...

Others
Bullish
1 hour ago
Slate Medicines appoints Mark W. Hahn to board to boost migraine drug development.

Slate Medicines appoints Mark W. Hahn to board to boost migraine drug development.

Slate Medicines, a biotech firm focused on migraine treatments, has appointed Mark W. Hahn to its Board of Directors. Hahn brings over 25 years of experience in life sciences, including leading companies through financial milestones and FDA approvals...

Company Fundamentals
Bullish
2 hours ago
Global clinical trials market to reach $176.32B by 2030, driven by AI and decentralized research advances

Global clinical trials market to reach $176.32B by 2030, driven by AI and decentralized research advances

The global clinical trials market is projected to grow from $135.51 billion in 2026 to $176.32 billion by 2030, at a CAGR of 6.8%. Growth is fueled by advances in AI-enabled trial design, decentralized and hybrid trial platforms, and increasing deman...

Market News
Bullish
4 hours ago
Projects near Sonoma water facilities cut wildfire risk, protecting key infrastructure.

Projects near Sonoma water facilities cut wildfire risk, protecting key infrastructure.

California American Water and Sonoma County Fire District completed projects reducing wildfire risk around water facilities in Sonoma County. The efforts included clearing flammable vegetation near critical infrastructure like water storage tanks and...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App